Measuring TBII antibodies when stopping Graves disease medication does not reliably predict whether the condition will return, as people with high and low levels of these antibodies have similar chances of relapse.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A meta-analysis of prospective studies comparing TBII at drug withdrawal with relapse outcomes could definitively determine whether TBII has any consistent predictive value across assays and populations.
A systematic review and meta-analysis of all prospective cohort studies measuring TBII (second-generation or M22 assay) at antithyroid drug withdrawal in Graves disease patients, reporting relapse over ≥18 months, with pooled sensitivity, specificity, and likelihood ratios.
An RCT could test whether omitting TBII testing in clinical decision-making leads to equivalent relapse rates compared to testing it, establishing its non-inferiority.
A multicenter RCT of 500 adults with Graves disease in euthyroidism after antithyroid drugs, randomized to TBII testing (with results guiding RAI referral) vs. no TBII testing (standard care). Primary outcome: relapse-free survival at 24 months.
A prospective cohort study could confirm whether TBII levels at withdrawal are unrelated to relapse risk in a larger, more diverse population than the original study.
A prospective cohort study of 250 adults with Graves disease achieving euthyroidism after antithyroid drugs, measuring TBII (B.R.A.H.M.S. assay, cutoff ≥1.5 IU/L) at withdrawal, then following them every 3 months for 24 months with blinded thyroid function testing.
A case-control study could compare TBII levels at withdrawal between relapsed and non-relapsed patients to determine if any association exists, even if weak.
A case-control study of 120 patients with Graves disease who relapsed within 24 months of drug withdrawal and 120 matched controls who remained in remission, comparing TBII levels at withdrawal using the same assay and cutoff, adjusting for age, sex, and treatment duration.
A cross-sectional study could estimate the prevalence of TBII positivity at drug withdrawal but cannot assess its predictive value.
A cross-sectional study measuring TBII levels at antithyroid drug withdrawal in 600 consecutive adults with Graves disease across multiple centers, reporting the proportion testing positive and correlating with baseline clinical features.